Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-ranging study of lebrikizumab in asthma
2009-013267-19Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Lebrikizumab dose-ranging with Placebo (2 arms). Primary endpoint: Primary efficacy outcome. Started Sep 2009; status: completed.
02
Drugs
lebrikizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2009-013267-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013267-19.